Laboratory testing of CYP2D6 alleles in relation to tamoxifen therapy

Genetics in Medicine

Volumn 14, Issue 12, 2012, Pages 990-1000

  Lyon, Elaine ^a   Gastier Foster, Julie ^b,c   Palomaki, Glenn E ^d   Pratt, Victoria M ^e   Reynolds, Kristen ^f   Fernanda Sabato M ^g   Scott, Stuart A ^h   Vitazka, Patrik ^g  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b NATIONWIDE CHILDREN S HOSPITAL   (United States)

^c THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^d BROWN UNIVERSITY   (United States)

^e QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

^f University of Louisville School of Medicine   (United States)

^g VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

^h MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

CYP2D6; laboratory guidelines; pharmacogenetics; tamoxifen

Indexed keywords

CYTOCHROME P450 2D6; ENDOXIFEN; TAMOXIFEN;

AFRICAN AMERICAN; ARTICLE; AUTOSOMAL RECESSIVE INHERITANCE; CAUCASIAN; CHROMOSOME; CHROMOSOME 22Q; CLINICAL DECISION MAKING; CLINICAL LABORATORY; COMMERCIAL PHENOMENA; DRUG MECHANISM; DRUG METABOLISM; ENZYME ACTIVITY; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; GENE AMPLIFICATION; GENE CONVERSION; GENE DELETION; GENE DOSAGE; GENE DUPLICATION; GENE EXPRESSION; GENE FREQUENCY; GENE MUTATION; GENETIC ANALYSIS; GENETIC VARIABILITY; GENOTYPE; GOOD LABORATORY PRACTICE; HAPLOTYPE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFORMATION PROCESSING; LABORATORY DIAGNOSIS; LABORATORY TEST; MEDICAL DOCUMENTATION; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; PHARMACOGENETICS; PHENOTYPE; PRACTICE GUIDELINE; PREDICTION; QUALITY CONTROL PROCEDURES; RECURRENCE RISK; VALIDATION STUDY; VALIDITY;

EID: 84870674888     PISSN: 10983600     EISSN: 15300366     Source Type: Journal    
DOI: 10.1038/gim.2012.108     Document Type: Article

References (39)

1. Lau CK, Subramaniam M, Rasmussen K, Spelsberg TC. Rapid induction of the c-jun protooncogene in the avian oviduct by the antiestrogen tamoxifen. Proc Natl Acad Sci USA 1991;88:829-833. (Pubitemid 21916117)
2. Desta Z, Ward BA, Soukhova NV, Flockhart DA. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther 2004;310:1062-1075. (Pubitemid 39108928)
3. Stearns V, Johnson MD, Rae JM, et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 2003;95:1758-1764. (Pubitemid 38008898)
4. Jin Y, Desta Z, Stearns V, et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 2005;97:30-39.
5. Ingelman-Sundberg M, Daly AK, Nebert DW (eds). The Human Cytochrome P450 (CYP) Allele Nomenclature Database. 2009. http://www. cypalleles. ki. se/. Accessed 26 October 2010.
6. Kirchheiner J, Nickchen K, Bauer M, et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry 2004;9:442-473. (Pubitemid 38903502)
7. Eap CB, Lima CA, Macciardi F, Woggon B, Powell K, Baumann P. Steady state concentrations of the enantiomers of mianserin and desmethylmianserin in poor and in homozygous and heterozygous extensive metabolizers of debrisoquine. Ther Drug Monit 1998;20:7-13. (Pubitemid 28110094)
8. Valdes RV, Payne D, Linder MW, et al. Guidelines and Recommendations for Laboratory Analysis and Application of Pharmacogenetics to Clinical Practice: DRAFT. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines. http://www. aacc. org/members/nacb/LMPG/OnlineGuide/ PublishedGuidelines/LAACP/Documents/PGx-Guidelines. pdf. Accessed 6 October 2010.
9. Wang B, Yang LP, Zhang XZ, Huang SQ, Bartlam M, Zhou SF. New insights into the structural characteristics and functional relevance of the human cytochrome P450 2D6 enzyme. Drug Metab Rev 2009;41:573-643.
10. Goetz MP, Rae JM, Suman VJ, et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 2005;23:9312-9318.
11. Goetz MP, Knox SK, Suman VJ, et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat 2007;101:113-121. (Pubitemid 47555336)
12. Bonanni B, Macis D, Maisonneuve P, et al. Polymorphism in the CYP2D6 tamoxifen-metabolizing gene influences clinical effect but not hot flashes: data from the Italian Tamoxifen Trial. J Clin Oncol 2006;24:3708-9; author reply 3709. (Pubitemid 46630548)
13. Wegman P, Elingarami S, Carstensen J, St O, Nordenskjd B, Wingren S. Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer. Breast Cancer Res 2007;9:R7.
14. Daly AK, Leathart JB, London SJ, Idle JR. An inactive cytochrome P450 CYP2D6 allele containing a deletion and a base substitution. Hum Genet 1995;95:337-341.
15. Marez D, Legrand M, Sabbagh N, et al. Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics 1997; 7:193-202. (Pubitemid 27290633)
16. The National Comprehensive Cancer Network (NCCN). http://www. nccn. org/professionals/physician-gls/PDF/breast. pdf. Accessed 29 October 2010.
17. Lash TL, Lien EA, Sensen HT, Hamilton-Dutoit S. Genotype-guided tamoxifen therapy: time to pause for reflection? Lancet Oncol 2009;10:825-833.
18. Borges S, Desta Z, Li L, et al. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther 2006;80:61-74. (Pubitemid 43946844)
19. Goetz MP, Kamal A, Ames MM. Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response. Clin Pharmacol Ther 2008;83:160-166.
20. Kiyotani K, Mushiroda T, Sasa M, et al. Impact of CYP2D6&z. ast;10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy. Cancer Sci 2008;99:995-999. (Pubitemid 351997603)
21. Ingle JN, Twito DI, Schaid DJ, et al. Combination hormonal therapy with tamoxifen plus fluoxymesterone versus tamoxifen alone in postmenopausal women with metastatic breast cancer. An updated analysis. Cancer 1991;67:886-891.
22. Schroth W, Antoniadou L, Fritz P, et al. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol 2007;25:5187-5193. (Pubitemid 350232249)
23. Lim HS, Ju Lee H, Seok Lee K, Sook Lee E, Jang IJ, Ro J. Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer. J Clin Oncol 2007;25:3837-3845. (Pubitemid 47477258)
24. Nowell SA, Ahn J, Rae JM, et al. Association of genetic variation in tamoxifenmetabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. Breast Cancer Res Treat 2005;91:249-258. (Pubitemid 40903087)
25. Wegman P, Vainikka L, St O, et al. Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients. Breast Cancer Res 2005;7:R284-R290.
26. Hayes DF, Stearns V, Rae J, Flockhart D; Consortium on Breast Cancer Pharmacogenomics. A model citizen? Is tamoxifen more effective than aromatase inhibitors if we pick the right patientS J Natl Cancer Inst 2008;100:610-613.
27. Schroth W, Goetz MP, Hamann U, et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 2009;302:1429-1436. 28 AmpliChip CYP450 Test for in vitro diagnostics use [package insert]. Roche Molecular Systems I: Branchburg, NJ, Catalog Number 04591445001-06. 2006.
28. Luminex xTAB CYP2D6 kit v. 3. http://www. luminexcorp. com/prod/groups/public/documents/lmnxcorp/306-cyp2d6-brochure. pdf. Accessed 21 August 2012.
29. Autogenomics. INFINITI CYP450 2D6I Assay application notes, 16 April 2009. http://www. autogenomics. com/pharma-2D6. php. Accessed 28 September 2010.
30. Molecular Pathology Checklist. College of American Pathologists. http://www. cap. org/apps/docs/education/lapaudio/pdf/052009-Presentation. pdf. 2010. Accessed 27 October 2010.
31. Lubin IM, McGovern MM, Gibson Z, et al. Clinician perspectives about molecular genetic testing for heritable conditions and development of a clinician-friendly laboratory report. J Mol Diagn 2009;11:162-171.
32. Centers for Disease Control. Genetic Testing Reference Materials Coordination Program (GeT-RM)-Home. http://wwwn. cdc. gov/dls/genetics/ rmmaterials/default. aspx. Accessed 31 December 2008.
33. Pratt VM, Zehnbauer B, Wilson JA, et al. Characterization of 107 genomic DNA reference materials for CYP2D6, CYP2C19, CYP2C9, VKORC1, and UGT1A1: a GeT-RM and Association for Molecular Pathology collaborative project. J Mol Diagn 2010;12:835-846.
34. Decisive Diagnostics. http://www. decisivedx. com/products/. Accessed 29 June 2012.
35. CAP Reference Resources and Publications, Genetics. http://www. cap. org/apps/cap. portal?-nfpb=true&cntvwrPtlt-actionOverride= %2Fportlets%2Fcon tentViewer%2Fshow&-windowLabel= cntvwrPtlt&cntvwrPtlt%7BactionForm. contentReference%7D= committees%2Fgenetics%2Fgenetics-index. html&-state=maximized&- pageLabel=cntvwr. Accessed 19 February 2011.
36. Bradford LD. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 2002;3:229-243. (Pubitemid 34223859)
37. Xie HG, Kim RB, Wood AJ, Stein CM. Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol 2001;41: 815-850. (Pubitemid 32385908)
38. Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clin Pharmacokinet 2009;48:689-723.
39. Sistonen J, Sajantila A, Lao O, Corander J, Barbujani G, Fuselli S. CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogenet Genomics 2007;17:93-101.